Literature DB >> 3627321

Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test.

A Garyfallos, I Magoula, G Tsapas.   

Abstract

The tubular transport of urate was studied in 47 uremic patients and in 20 normal subjects using probenecid and pyrazinamide tests. There was a marked increase in urate excretion per nephron as the renal function deteriorated. Presecretory reabsorption of urate per nephron, which was almost complete in normal subjects, showed a diminution with increasing severity of chronic renal failure. Until the creatinine clearance had decreased to less than 10 ml/min, the secreted urate per nephron remained almost constant, while in the end stage of renal failure it was markedly decreased. With the progression of renal disease, the postsecretory reabsorption of urate per nephron diminished. In patients with a creatinine clearance less than 10 ml/min, it was 4 times lower than in normal subjects. These findings indicate that urate secretion does not contribute to the increase of urate excretion per nephron at any level of renal failure, whereas the impairment of both reabsorptive components accounts for the augmented urate excretion per nephron in uremic patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3627321     DOI: 10.1159/000184368

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Authors:  Garry G Graham; Diluk R W Kannangara; Sophie L Stocker; Ian Portek; Kevin D Pile; Praveen L Indraratna; Indira Datta; Kenneth M Williams; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 4.  Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Authors:  Garry G Graham; Sophie L Stocker; Diluk R W Kannangara; Richard O Day
Journal:  Curr Rheumatol Rep       Date:  2018-06-21       Impact factor: 4.592

5.  A proposal for identifying the low renal uric acid clearance phenotype.

Authors:  Praveen L Indraratna; Sophie L Stocker; Kenneth M Williams; Garry G Graham; Graham Jones; Richard O Day
Journal:  Arthritis Res Ther       Date:  2010-12-16       Impact factor: 5.156

6.  The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3.

Authors:  Simeng Liu; Yijun Gong; Hong Ren; Wen Zhang; Xiaonong Chen; Tong Zhou; Xiao Li; Nan Chen
Journal:  Oncotarget       Date:  2017-07-06

7.  Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.

Authors:  Diluk R W Kannangara; Sheena N Ramasamy; Praveen L Indraratna; Sophie L Stocker; Garry G Graham; Graham Jones; Ian Portek; Kenneth M Williams; Richard O Day
Journal:  Arthritis Res Ther       Date:  2012-08-17       Impact factor: 5.156

8.  Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study.

Authors:  Fengqin Li; Hui Guo; Jianan Zou; Weijun Chen; Yijun Lu; Xiaoli Zhang; Chensheng Fu; Jing Xiao; Zhibin Ye
Journal:  BMC Nephrol       Date:  2018-04-24       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.